Clinical Trial - Trial jRCT2031230369
Access comprehensive clinical trial information for jRCT2031230369 through Pure Global AI's free database. This phase not specified trial is sponsored by Novo Nordisk Pharma Ltd. and is currently Recruiting. The study focuses on Type 2 diabetes.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
jRCT2031230369
Recruiting
Trial Details
Japan Registry Clinical Trial • jRCT2031230369
Untitled Trial
Efficacy and safety of co administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4/2.4 mg and 1.0/1.0 mg once weekly versus semaglutide 2.4 mg and 1.0 mg, cagrilintide 2.4 mg and placebo in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor(NN9388 4896) (REIMAGINE2)
Study Focus
Interventional
Sponsor & Location
Novo Nordisk Pharma Ltd.
Argentina;Australia;Brazil;Bulgaria;Canada;China;Colombia;Croatia;Czech;Denmark;Finland;Germany;Gree
Timeline & Enrollment
N/A
N/A
N/A
ICD-10 Classifications
Type 2 diabetes mellitus
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus with multiple complications
Data Source
Japan Registry Clinical Trial
jRCT2031230369
Non-Device Trial